Pay in 4 interest-free payments of $7.04 Learn more
Ships within 48 hours · Estimated delivery Nov 7 - Nov 12
Molecular Characteristics Compound Name: Tesamorelin + CJC-1295 + Ipamorelin Blend Tesamorelin CAS Number: 901758-09-6 CJC-1295 (No DAC) CAS Number: 446262-90-4 Ipamorelin CAS Number: 170851-70-4 Peptide Class: Growth hormone axis research peptides Form: Lyophilized peptide powder blend Unit Size: 12 mg research blend Stability Profile and Storage Recommendations Store lyophilized peptide blend at 20C Protect from moisture and direct light Avoid repeated freezethaw cycles Reconstitute using sterile laboratory-grade solvent Seal vial tightly after each use Solubility and Preparation Considerations Soluble in sterile aqueous laboratory solutions Compatible with buffered peptide research systems Applicable in endocrine signaling assays Suitable for receptor interaction experiments Compatible with molecular biology and peptide research protocols Technical Specifications product Name Tesamorelin + CJC-1295 + Ipamorelin 12mg Blend brand BioPeptides purity Research-grade analytical quality form Lyophilized peptide powder blend synthesis Solid-phase peptide synthesis (SPPS) analytical Identity and purity verification molecular Structure Triple-peptide GH signaling formulation stability Stable under 20C storage conditions Analytical Validation and Quality Assurance Molecular identity verification for all three peptides Purity and stability assessment Structural integrity testing Batch-to-batch consistency validation Analytical quality control inspection Regulatory and Compliance Statement This peptide blend supplied by BioPeptides is intended strictly for laboratory research use only
The bulking phase is simply the opposite of this Making sure theres plenty of calories to support the metabolism and muscle growth, without the worry of going catabolic
Glutathione works on a cellular level in each of your bodys cells, so it also aids with everything from immune health to skin health to cellular repair
Peptidomimetics for receptor ligands
doi:10.1152/ajpheart.00595.2018 64
/assets/images/provider/photos/2813769.png)
